United Therapeutics Earnings Reports

United Therapeutics posted a record-breaking Q3 2025 with $799.5 million in revenue and $338.7 million in net income, as growth in Tyvaso DPI and Orenitram offset declines in other product lines. Operating income rose to $388.5 million with a focus on sustained momentum through new therapies.

United Therapeutics reported Q2 2025 revenue of $798.6 million and net income of $309.5 million, fueled by double-digit growth in key products including Tyvaso DPI and Orenitram. EPS reached $6.41 diluted, with a strong performance across their pulmonary hypertension portfolio.

The company delivered a strong Q1 2025, achieving record revenues of $794.4 million, driven by growth in Tyvaso DPI and expanded market presence in pulmonary hypertension treatments.

United Therapeutics reported Q4 2024 revenue of $735.9 million, driven by significant growth in Tyvaso and Orenitram. The company achieved net income of $301.3 million and an EPS of $6.74. Adjusted EPS was $6.19. Strong performance across key product lines contributed to a robust quarter.

United Therapeutics reported a strong third quarter in 2024, with total revenues growing by 23% year-over-year to $748.9 million. The company achieved a $3 billion annual revenue run rate and saw significant growth in Tyvaso revenues. They are anticipating clinical data reads and regulatory events to further propel growth.

United Therapeutics reported a 20% year-over-year increase in total revenues, reaching $714.9 million in the second quarter of 2024, compared to $596.5 million in the second quarter of 2023. The growth was primarily driven by Tyvaso, Remodulin, Orenitram and Unituxin.

United Therapeutics reported a 34% increase in total revenues to $677.7 million for Q1 2024, compared to $506.9 million in Q1 2023. Net income increased by 27% to $306.6 million. The company also implemented a $1 billion accelerated share repurchase program.

United Therapeutics reported a record $614.7 million in revenue for Q4 2023, a 25% increase compared to Q4 2022. Net income for the quarter was $217.1 million, up from $132.1 million in the same period last year. The company's growth was primarily driven by its Tyvaso business, with Tyvaso DPI showing significant gains.

United Therapeutics reported an 18% year-over-year increase in total revenues for Q3 2023, reaching $609.4 million compared to $516.0 million in Q3 2022. Net income also increased by 12% to $267.6 million.

United Therapeutics reported a 28% year-over-year increase in total revenues, reaching $596.5 million, driven by strong performance from Tyvaso and Orenitram. The company's net income also saw a significant increase of 123% to $259.2 million.

United Therapeutics Corporation announced its Q1 2023 financial results, with total revenues growing 10% year-over-year to $506.9 million. The company's performance was driven by the Tyvaso franchise and record revenues from Orenitram. Net income remained relatively flat at $240.9 million compared to $239.9 million in the same quarter of the previous year.

United Therapeutics Corporation reported a record full year total revenue of $1.94 billion, with U.S. patients being treated with treprostinil-based therapies reaching an all-time high during the fourth quarter of 2022. The company is focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support their long-term goal of doubling revenue to a $4 billion run rate by the end of 2025.

United Therapeutics Corporation reported a 16% year-over-year increase in total revenues for the third quarter of 2022, reaching $516.0 million compared to $444.7 million in the third quarter of 2021. Net income also increased by 47% to $239.3 million, compared to $162.7 million in the same period of the previous year.

United Therapeutics reported a 5% year-over-year increase in total revenues for Q2 2022, reaching $466.9 million. This growth was primarily driven by increased sales of Tyvaso. However, net income decreased by 33% to $116.0 million compared to the same period in the previous year, impacted by increased operating expenses and other expenses.

United Therapeutics reported a 22% increase in total revenue to $461.9 million for the first quarter of 2022, compared to $379.1 million in the first quarter of 2021. Net income saw a substantial rise to $239.9 million, a 748% increase from $28.3 million in the same period last year. The company is progressing with its phase 3 studies and anticipates potential FDA approval for Tyvaso DPI.

United Therapeutics Corporation announced its Q4 and full year 2021 financial results. Full year total revenues rose to $1,686 million, driven by an all-time high in U.S. patients being treated with the company’s treprostinil-based therapies during the fourth quarter of 2021.

United Therapeutics Corporation announced its Q3 2021 financial results, with total revenue growing 17% year over year to $444.7 million. The company is progressing with six phase 3 clinical trials across various forms of pulmonary hypertension and pulmonary fibrosis and continues to add new Tyvaso patients, reaching approximately 4,000 U.S. patients on Tyvaso therapy at the end of the third quarter.

United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2021, with total revenue growing by 23% year over year to $446.5 million. The company is focused on expanding its medical options for PAH and progressing in phase 3 studies.

United Therapeutics reported a 6% year-over-year increase in total revenue, reaching $379.1 million in the first quarter of 2021. The company also saw net income decrease by 79% to $28.3 million, and non-GAAP earnings increased by 2% to $162.1 million.

United Therapeutics Corporation reported a rise in full year net revenue to $1,483 million and U.S. patients being treated with the company's treprostinil-based therapies reached an all-time high during the fourth quarter.

United Therapeutics reported a decrease in total revenues by 5% year-over-year, but experienced growth in Orenitram® and Tyvaso® net revenues. Net income increased by 29% and the company is preparing for multiple product launches in 2021.

United Therapeutics reported a decrease in total revenues by 3% compared to the same quarter last year, with net income also declining by 48%. However, Orenitram revenue saw a significant increase of 40% year-over-year. The company is preparing for potential growth with upcoming product launches and label expansions.

United Therapeutics Corporation announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 million year-over-year. First quarter diluted earnings per share (EPS) was $3.12 compared to an $11.32 per share loss in the first quarter of 2019. Non-GAAP diluted EPS of $3.61 was up 1% from the first quarter of 2019.

United Therapeutics Corporation reported a decrease in quarterly net revenue by 18% to $311 million compared to the prior year, primarily due to a $43.6 million decrease in purchases of treprostinil-based products by a U.S. distributor adjusting inventory levels.